Hormone Modulating Therapy for Breast Cancer may be Linked with Lower Dementia risk
New Delhi: Hormone Modulating Therapy (HMT) is indeed used in treating certain types of breast cancer, particularly those that are hormone receptor-positive. HMT works by blocking the body’s natural hormones, such as estrogen, which can promote the growth of breast cancer cells.
Recent research has indicated that HMT might also be associated with a lower risk of developing Alzheimer’s disease and related dementias. The exact mechanisms behind this protective effect are still being studied, but it is thought that hormones, especially estrogen, play a role in brain health and cognitive function.
However, it’s important to consult healthcare providers for personalized medical advice, as the benefits and risks of HMT can vary depending on individual health conditions and medical history.
A new study has found that Hormone Modulating Therapy (HMT) used for the treatment of breast cancer is associated with a 7% lower risk of developing Alzheimer’s disease and related dementia later in life. This research highlights the potential cognitive benefits of HMT beyond its primary use in combating hormone receptor-positive breast cancer. The findings suggest that the hormonal regulation provided by HMT could play a role in protecting against neurodegenerative diseases.
To improve understanding about the risk of Alzheimer’s disease and related dementias (ADRD) following Hormone Modulating Therapy (HMT) in breast cancer patients, researchers Modugno and Chao Cai, Ph.D., an assistant professor at the University of South Carolina College of Pharmacy, conducted a study. They used a federal database of people aged 65 and older to identify women who were diagnosed with breast cancer between 2007 and 2009. These women did not have a previous ADRD diagnosis or a history of using HMT before their breast cancer diagnosis. By focusing on this specific cohort, the researchers aimed to isolate the effects of HMT on the subsequent development of ADRD.
FOLLOW FOR MORE.
